Site search

Clear filter
2898 results for '' found
Multivessel compared to Single Vessel Functional Angiography to Diagnose Patients with No Obstructive Coronary Artery Disease: The MAD-NOCA trial (ACTRN12622001521718)
Multivessel compared to Single Vessel Functional Angiography to Diagnose Patients with No Obstructive Coronary Artery Disease: The MAD-NOCA trial (ACTRN12622001521718)
/
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAM
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAM
/
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Ce
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Ce
/
Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (NCT05618028)
Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (NCT05618028)
/
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection (NCT04903626)
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection (NCT04903626)
/
A Type II Hybrid Effectiveness-Implementation, Randomised Control Trial of Left Write Hook for Adult Survivors of Child Sexual Abuse (ACTRN12624000862549)
A Type II Hybrid Effectiveness-Implementation, Randomised Control Trial of Left Write Hook for Adult Survivors of Child Sexual Abuse (ACTRN12624000862549)
/
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
/